Magazin
2006-09-14
Wellesley Hills, Massachusetts (ots/PRNewswire) -
MacroChem Corporation (OTC Bulletin Board: MACM), a specialtypharmaceutical company that develops and seeks to commercializepharmaceutical products based on proprietary drug deliverytechnologies, has retained The Investor Relations Group, Inc. (IRG),a full-service investor relations firm, to serve as its new investorrelations and corporate communications agency.
"The Investor Relations Group will play an integral role inensuring that MacroChem reaches the investment community byincorporating a more proactive program," said Robert DeLuccia,President and CEO of MacroChem Corporation. "We believe IRG will alsohelp us deliver our Company messages more effectively to investorsand financial sources."
IRG will strive to increase investor and industry awareness ofMacroChem and its products within the U.S. and world markets byintroducing the Company and its Management to pre-qualified fundmanagers and analysts, as well as to financial and industry mediasources.
About MacroChem
MacroChem Corporation is a specialty pharmaceutical company withtwo clinical development stage products containing our patentedenhancer, SEPA(R): EcoNail, to treat fungal infection of the nail andOpterone(R), to treat male hypogonadism. In addition to our SEPAtechnology, we are also evaluating applications for MacroDerm(TM),our patented series of polymers that impede penetration of activeingredients through the skin. For more information visit our website,http://www.macrochem.com.
About The Investor Relations Group, Inc.
The Investor Relations Group, Inc. (IRG), founded in 1996,represents select publicly traded companies, with a uniquespecialization in assisting quality under-followed companies. IRGarranges one-on-one meetings for its portfolio companies withpre-qualified money managers, handling investment portfolios thatrange from US$10 million to US$10 billion+, selected from itsproprietary contact base of more than 50,000 qualified fund managerswith an investing history in small-cap stocks. IRG is a full-servicecorporate communications company that, among other related offerings,produces all client press releases, manages shareholdercommunications and acts as primary contact for the investingcommunity. IRG also houses a full-service public relations arm thatspecializes in building awareness of its companies within thefinancial and trade media, as well as the public at large.
Forward-Looking Statements
With the exception of historical information contained in thispress release, the matters described herein are forward-lookingstatements that involve risks and uncertainties. MacroChem's actualresults may differ significantly from the results discussed in theforward-looking statements. Factors that might cause such adifference include, but are not limited to, those discussed orreferred to in the section entitled "Risk Factors" in MacroChem'sAnnual Report on Form 10-K, as well as those discussed elsewheretherein, and include, without limitation, risks regarding productdevelopment, the timing and results of clinical trials, theregulatory approval process, capital requirements, financialcondition, patent protection and dependence on third parties fordevelopment and licensing arrangements. Readers are cautioned not toplace undue reliance on these forward-looking statements, which speakonly as of the date hereof. MacroChem undertakes no obligation toupdate publicly any forward-looking statements, whether as a resultof new information, future events or otherwise. For more informationvisit our website, http://www.macrochem.com.
Contact: MacroChem Corp.: Bernard Patriacca - VP/CFO +1-781-489-7310 Investor Relations: The Investor Relations Group, Inc. Jordan Silverstein/Christine Berni +1-212-825-3210
Web site: http://www.macrochem.com
ots Originaltext: MacroChem CorporationIm Internet recherchierbar: http://www.presseportal.de
Contact:Bernard Patriacca, VP/CFO of MacroChem Corp., +1-781-489-7310; or Jordan Silverstein or Christine Berni of The Investor Relations Group, Inc., +1-212- 825-3210
MacroChem Retains The Investor Relations Group
MacroChem Corporation (OTC Bulletin Board: MACM), a specialtypharmaceutical company that develops and seeks to commercializepharmaceutical products based on proprietary drug deliverytechnologies, has retained The Investor Relations Group, Inc. (IRG),a full-service investor relations firm, to serve as its new investorrelations and corporate communications agency.
"The Investor Relations Group will play an integral role inensuring that MacroChem reaches the investment community byincorporating a more proactive program," said Robert DeLuccia,President and CEO of MacroChem Corporation. "We believe IRG will alsohelp us deliver our Company messages more effectively to investorsand financial sources."
IRG will strive to increase investor and industry awareness ofMacroChem and its products within the U.S. and world markets byintroducing the Company and its Management to pre-qualified fundmanagers and analysts, as well as to financial and industry mediasources.
About MacroChem
MacroChem Corporation is a specialty pharmaceutical company withtwo clinical development stage products containing our patentedenhancer, SEPA(R): EcoNail, to treat fungal infection of the nail andOpterone(R), to treat male hypogonadism. In addition to our SEPAtechnology, we are also evaluating applications for MacroDerm(TM),our patented series of polymers that impede penetration of activeingredients through the skin. For more information visit our website,http://www.macrochem.com.
About The Investor Relations Group, Inc.
The Investor Relations Group, Inc. (IRG), founded in 1996,represents select publicly traded companies, with a uniquespecialization in assisting quality under-followed companies. IRGarranges one-on-one meetings for its portfolio companies withpre-qualified money managers, handling investment portfolios thatrange from US$10 million to US$10 billion+, selected from itsproprietary contact base of more than 50,000 qualified fund managerswith an investing history in small-cap stocks. IRG is a full-servicecorporate communications company that, among other related offerings,produces all client press releases, manages shareholdercommunications and acts as primary contact for the investingcommunity. IRG also houses a full-service public relations arm thatspecializes in building awareness of its companies within thefinancial and trade media, as well as the public at large.
Forward-Looking Statements
With the exception of historical information contained in thispress release, the matters described herein are forward-lookingstatements that involve risks and uncertainties. MacroChem's actualresults may differ significantly from the results discussed in theforward-looking statements. Factors that might cause such adifference include, but are not limited to, those discussed orreferred to in the section entitled "Risk Factors" in MacroChem'sAnnual Report on Form 10-K, as well as those discussed elsewheretherein, and include, without limitation, risks regarding productdevelopment, the timing and results of clinical trials, theregulatory approval process, capital requirements, financialcondition, patent protection and dependence on third parties fordevelopment and licensing arrangements. Readers are cautioned not toplace undue reliance on these forward-looking statements, which speakonly as of the date hereof. MacroChem undertakes no obligation toupdate publicly any forward-looking statements, whether as a resultof new information, future events or otherwise. For more informationvisit our website, http://www.macrochem.com.
Contact: MacroChem Corp.: Bernard Patriacca - VP/CFO +1-781-489-7310 Investor Relations: The Investor Relations Group, Inc. Jordan Silverstein/Christine Berni +1-212-825-3210
Web site: http://www.macrochem.com
ots Originaltext: MacroChem CorporationIm Internet recherchierbar: http://www.presseportal.de
Contact:Bernard Patriacca, VP/CFO of MacroChem Corp., +1-781-489-7310; or Jordan Silverstein or Christine Berni of The Investor Relations Group, Inc., +1-212- 825-3210
MacroChem Corporation
| Preisvergleich Medikamente |
|
In Zusammenarbeit mit Medizinfuchs |
